Lixte Biotechnology Holdings, Inc. (LIXT) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
LIXT Revenue Growth
LIXT Revenue Analysis (2013–2024)
As of May 8, 2026, Lixte Biotechnology Holdings, Inc. (LIXT) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, LIXT's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $200,000 in 2015.
When compared to Healthcare sector peers including CASI (+21.7% YoY), NKTR (-43.9% YoY), and AGIO (+78.3% YoY). Compare LIXT vs CASI →
LIXT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| LIXTCurrent | $0 | - | - | - | |
 CASI | $29M | +21.7% | +47.2% | -138.8% | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% | |
 AGIO | $54M | +78.3% | - | -873.9% |
LIXT Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $0 | - | $-3,572,789 | - |
| 2023 | $0 | - | $0 | - | $-5,090,236 | - |
| 2022 | $0 | - | $0 | - | $-6,311,481 | - |
| 2021 | $0 | - | $0 | - | $-6,720,445 | - |
| 2020 | $0 | - | $0 | - | $-3,266,440 | - |
| 2019 | $0 | - | $0 | - | $-2,490,066 | - |
| 2018 | $0 | - | $0 | - | $-2,138,051 | - |
| 2017 | $0 | - | $0 | - | $-1,809,789 | - |
| 2016 | $0 | -100.0% | $0 | - | $-2,134,915 | - |
| 2015 | $200K | - | $200K | 100.0% | $-2,646,000 | -1323.0% |
See LIXT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LIXT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LIXT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLIXT — Frequently Asked Questions
Quick answers to the most common questions about buying LIXT stock.
Is LIXT's revenue growth accelerating or slowing?
LIXT TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is LIXT's long-term revenue growth rate?
Lixte Biotechnology Holdings, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is LIXT's revenue distributed by segment?
LIXT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.